T. Rowe Price Associates’s Janux Therapeutics JANX Stock Holding History

T. Rowe Price Associates’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$818K	Sell	58,800 -685,666	-92%	-$9.4M	﹤0.01%	2241
2025 Q4	$10.3M	Sell	744,466 -521,090	-41%	-$12.3M	﹤0.01%	1230
2025 Q3	$30.9M	Sell	1,265,556 -527,871	-29%	-$12.9M	﹤0.01%	944
2025 Q2	$41.4M	Buy	1,793,427 +400,601	+29%	+$10.6M	﹤0.01%	775
2025 Q1	$37.6M	Buy	1,392,826 +282,848	+25%	+$10.7M	﹤0.01%	805
2024 Q4	$59.4M	Buy	1,109,978 +950,557	+596%	+$50.3M	0.01%	702
2024 Q3	$7.24M	Sell	159,421 -92,937	-37%	-$4.04M	﹤0.01%	1203
2024 Q2	$10.6M	Buy	252,358 +232,762	+1,188%	+$10.9M	﹤0.01%	1103
2024 Q1	$739K	Buy	+19,596	New	+$427K	﹤0.01%	2040

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates's JANX Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Janux Therapeutics (JANX) stake by 92% in Q1 2026, selling an estimated $9.4M and leaving 58,800 shares worth $818K. The position accounts for ﹤0.01% of the portfolio, ranked #2241.

T. Rowe Price Associates first reported a position in JANX in Q1 2024 and has held it in 9 quarters since. The position peaked at $59.4M in Q4 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

T. Rowe Price Associates held 58,800 shares of Janux Therapeutics worth $818K as of Q1 2026.
T. Rowe Price Associates sold 685,666 Janux Therapeutics shares in Q1 2026, an estimated $9.4M.
Janux Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2241 holding.
T. Rowe Price Associates first reported a position in Janux Therapeutics in Q1 2024 and has held it in 9 quarters since.
T. Rowe Price Associates's Janux Therapeutics position peaked at $59.4M in Q4 2024.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.